Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.

In conclusion, homozygous CDKN2A deletion is rare and could be used to predict response to CDK4/6 inhibitors in association with other genomic features. We encourage further trials in this direction.
PMID: 31709901 [PubMed - as supplied by publisher]

Source: Cancer Biology and Therapy - November 9, 2019 Category: Cancer & Oncology Authors: Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P Tags: Cancer Biol Ther Source Type: research